Suggested remit: To appraise the clinical and cost effectiveness of imlunestrant within its marketing authorisation for treating oestrogen receptor-positive, HER2-negative advanced breast cancer after endocrine treatment.
 
Status In progress
Technology type Medicine
Decision Awaiting decision
Process STA Standard
ID number 6373

Provisional Schedule

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6373 25 April 2024 - 24 May 2024

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
25 April 2024 In progress. Scoping commencing
25 October 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
25 October 2023 Topic selection

For further information on our processes and methods, please see our CHTE processes and methods manual